Pittsburgh -Topical tacrolimus ointment 0.1 percent (Protopic) may be a viable addition to the current therapeutic armamentarium for early-stage cutaneous T-cell lymphoma (CTCL), Larisa Geskin, M.D., said.
Insights into Bimekizumab 2-Year Data for PsA, nr-asSpA, and AS
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Deep Histological Margins Do Not Increase cSCC Recurrence Risk if Tumor is Fully Excised
The Cutaneous Connection: Enhancing Vitiligo Care With Nanette Silverberg, MD
Latex Gloves and the Americans With Disabilities Act
Live From Chicago: Bringing Sun Protection Awareness to Communities